VINC

Vincerx Pharma Inc. (VINC) | Rumor.io

Vincerx Pharma

VINC

Attention (50-day avg)0%

Attention rank (50-day avg)#4,706

Bullish sentiment (50-day avg)—

Price to earnings ratio-0

Market capitalization78.5K

Earnings per share-5.79

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-30.1M

Social

What share of all stock conversation is about VINC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% new	0% 0

Mar 19

Vincerx Pharma, Inc. (VINC) has a cash runway out to Q3 2026, and potentially longer, due to $3M in quarterly trial expense savings.
The company's CDK9 inhibitor, SLS009, may be approved by the FDA with as low as 25% response rates, based on comments from Drs. Z and K.
The merger with Ogory, Inc. does not guarantee a $15M minimum cash commitment for VINC shareholders, only targets it as a possible outcome.

Generated by AI

Sentiment

Of the messages about VINC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95% +12.58
Bearish	—	—	—	5% -12.58

Bullish· Mar 18

The CEO of Vincerx Pharma has secured a $385 million merger, providing a long runway for the company until Q3 2026, with potential for even longer due to reduced trial expenses.
The company's CDK9 inhibitor, 009, has shown promising results, with response rates approaching 12 months+ vs 2.5 weeks for similar treatments, and may only need 25% response rates for FDA approval.
The asset's low float and potential for shorts covering could lead to increased demand and price appreciation, with some analysts predicting a potential run to $1.50 to $2.00 or even $5.00.

Bearish· Jan 29

The market may not like Vincerx Pharma, Inc. due to a lack of confidence in the company.
Vincerx Pharma, Inc. has been involved in a dilution scam, selling a large number of shares to investors.
The company's recent actions, including a reverse stock split and a large-scale share sale, may indicate a lack of trustworthiness and a potential scam.

Generated by AI

Topics

Of the messages about VINC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	97.35%
Analysts	0%	0%	0%	0%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	2.65%

Sep 16

Vincerx Pharma, Inc. (VINC) announces a $50 million private placement at $14.50 per share.
The private placement was led by new and existing investors, including Deerfield Management Company, Rock Springs Capital, Point72 Asset Management, and Sphera Healthcare.
Vincerx Pharma expects to close the private placement on or about September 20, 2021, subject to customary closing conditions.

Generated by AI

Community

Of the messages about VINC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	16.03%
Newcomers	0%	0%	0%	83.97%

Dec 14

Vincerx Pharma, Inc. ($VINC) received FDA approval to proceed with its IND application for a first human study in advanced or metastatic solid tumors, expected to commence in Q1 2023.
New investors are focusing on the company's potential for growth, with one user noting a 40.2% increase in price and another stating that the stock is "sexy."
The FDA news has caused bears to become concerned, with one user noting that the bears didn't expect the news, and another user encouraging others to "punish the shorts."

Generated by AI

Also Discussed

Investors talking about VINC also mention

#	Name	Attention
1	KRON - Kronos Bio, Inc.	——
2	ACHL - Achilles Therapeutics plc	——
3	ADC Therapeutics S.A.ADCT	0%0
4	C4 Therapeutics IncCCCC	0.01%new
5	Replimune Group, Inc.REPL	0%0
6	AMAM - Ambrx Biopharma Inc.	——
7	ELEV - Elevation Oncology, Inc.	——
8	Pyxis Oncology, Inc. Common StockPYXS	0%0
9	Cullinan Therapeutics Inc.CGEM	0%new
10	LVTX - LAVA Therapeutics N.V.	——

Vincerx Pharma Inc.

Healthcare
Biotechnology

Vincerx Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies to address unmet medical needs in cancer treatment. It leverages expertise in oncology to advance antibody-drug conjugates, small molecule drug conjugates, a CDK9 inhibitor, and the VersAptx bioconjugation platform for next-generation targeted therapies. The company engages in research, development, manufacturing, commercialization, sublicensing, and distribution of its clinical-stage and preclinical programs within the biotechnology sector. Currently, Vincerx Pharma Inc. is pursuing a Plan of Liquidation and Dissolution, with its board unanimously recommending stockholder approval to enable potential distributions from remaining assets while winding down operations. This process includes evaluating strategic alternatives such as out-licensing and asset sales. Headquartered in Palo Alto, California, and founded in 2018, Vincerx Pharma Inc. operates in the United States, contributing to the oncology pipeline through its specialized drug development efforts.

Website

Location

1825 S. Grant Street

San Mateo, CA, 94402

United States

Social

What share of all stock conversation is about VINC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% new	0% 0

Mar 19

Vincerx Pharma, Inc. (VINC) has a cash runway out to Q3 2026, and potentially longer, due to $3M in quarterly trial expense savings.
The company's CDK9 inhibitor, SLS009, may be approved by the FDA with as low as 25% response rates, based on comments from Drs. Z and K.
The merger with Ogory, Inc. does not guarantee a $15M minimum cash commitment for VINC shareholders, only targets it as a possible outcome.

Generated by AI

Sentiment

Of the messages about VINC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95% +12.58
Bearish	—	—	—	5% -12.58

Bullish· Mar 18

The CEO of Vincerx Pharma has secured a $385 million merger, providing a long runway for the company until Q3 2026, with potential for even longer due to reduced trial expenses.
The company's CDK9 inhibitor, 009, has shown promising results, with response rates approaching 12 months+ vs 2.5 weeks for similar treatments, and may only need 25% response rates for FDA approval.
The asset's low float and potential for shorts covering could lead to increased demand and price appreciation, with some analysts predicting a potential run to $1.50 to $2.00 or even $5.00.

Bearish· Jan 29

The market may not like Vincerx Pharma, Inc. due to a lack of confidence in the company.
Vincerx Pharma, Inc. has been involved in a dilution scam, selling a large number of shares to investors.
The company's recent actions, including a reverse stock split and a large-scale share sale, may indicate a lack of trustworthiness and a potential scam.

Generated by AI

Topics

Of the messages about VINC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	97.35%
Analysts	0%	0%	0%	0%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	2.65%

Sep 16

Vincerx Pharma, Inc. (VINC) announces a $50 million private placement at $14.50 per share.
The private placement was led by new and existing investors, including Deerfield Management Company, Rock Springs Capital, Point72 Asset Management, and Sphera Healthcare.
Vincerx Pharma expects to close the private placement on or about September 20, 2021, subject to customary closing conditions.

Generated by AI

Community

Of the messages about VINC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	16.03%
Newcomers	0%	0%	0%	83.97%

Dec 14

Vincerx Pharma, Inc. ($VINC) received FDA approval to proceed with its IND application for a first human study in advanced or metastatic solid tumors, expected to commence in Q1 2023.
New investors are focusing on the company's potential for growth, with one user noting a 40.2% increase in price and another stating that the stock is "sexy."
The FDA news has caused bears to become concerned, with one user noting that the bears didn't expect the news, and another user encouraging others to "punish the shorts."

Generated by AI

Vincerx Pharma

Social

Mar 19

Sentiment

Bullish· Mar 18

Bearish· Jan 29

Topics

Sep 16

Community

Dec 14

Also Discussed

Vincerx Pharma Inc.

Company Information

Location

Also Discussed

Social

Mar 19

Sentiment

Bullish· Mar 18

Bearish· Jan 29

Topics

Sep 16

Community

Dec 14